<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603497</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-PK11</org_study_id>
    <nct_id>NCT02603497</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal Function</brief_title>
  <official_title>Pharmacokinetic (PK) Study of ASP015K -Evaluation of Pharmacokinetics in Patients With Impaired Renal Function and Subjects With Normal Renal Function-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the pharmacokinetics of ASP015K in patients with
      impaired renal function and subjects with normal renal function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) parameter of ASP015K: AUCinf</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP015K: Cmax</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>Cmax: Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of metabolites: AUCinf</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of metabolites: Cmax</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Adverse Events (AEs)</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Vital signs</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>Supine blood pressure, supine pulse rate and axillary body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Laboratory tests</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>Hematology, blood biochemistry and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by 12-lead ECGs</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>ECG: Electrocardiogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: AUClast</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>AUClast: Area under the concentration-time curve from the time of dosing extrapolated to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: t1/2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: tmax</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>tmax: Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: CL/F</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: Vz/F</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>Vz/F: Apparent volume of distribution during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of metabolites: AUClast</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of metabolites: t1/2</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of metabolites: tmax</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Patients With Impaired Renal Function</condition>
  <arm_group>
    <arm_group_label>Control (Subjects with normal renal function)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP015K</intervention_name>
    <description>oral</description>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_label>Control (Subjects with normal renal function)</arm_group_label>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_label>Moderate renal impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subject

          -  Body weight): ≥40.0 kg and &lt;90.0 kg

          -  Body mass index BMI: ≥17.6 and &lt;30.0

          -  Female subject must either:

               -  Be post-menopausal or surgically sterile.

               -  Agree not to try to become pregnant starting at the time of informed consent
                  throughout the study period and for 60 days after the final study drug
                  administration if she is of childbearing potential.

          -  Female subjects who agree not to breastfeed starting at informed consent and
             throughout the study period and for 60 days after the final study drug administration

          -  Agree not to donate ova for female / sperm for male starting at informed consent and
             throughout the study period and for 60/90 days after the final study drug
             administration

          -  Agree to use highly effective contraception

        Patients with impaired renal function

          -  Patients with eGFR by GFR predictive equation for Japanese within the following ranges
             at screening and who is not undergoing dialysis.

               -  Patients with mild impaired renal function (eGFR; ≥60 mL/min/1.73 m2 and &lt;90
                  mL/min/1.73 m2)

               -  Patients with moderate impaired renal function (eGFR; ≥30 mL/min/1.73 m2 and &lt;60
                  mL/min/1.73 m2)

               -  Patients with severe impaired renal function (eGFR; ≥15 mL/min/1.73 m2 and &lt;30
                  mL/min/1.73 m2)

          -  Patients whose treatment regimen (including diet) for renal impairment or
             complications remain unchanged within 14 days prior to hospital admission day (Day
             -1), or patients who receive treatments (including diet) that need not to be changed
             during the period from 14 days before hospital admission day (Day -1) to follow-up
             examination in the opinion of the investigator or sub-investigator.

        Subjects with normal renal function

          -  Subjects with eGFR by GFR predictive equation for Japanese ≥ 90 mL/min/1.73 m2 at
             screening

          -  Subjects who is healthy, as judged by the investigator or sub-investigator based on
             physical examinations (subjective symptoms and objective findings) and all tests
             obtained at screening and during the period from hospital admission to immediately
             before study drug administration

        Exclusion Criteria:

        All subjects

          -  Received or is scheduled to receive any study drugs in other clinical trials or
             post-marketing studies within 120 days before screening or during the period from
             screening to the hospital admission day (Day -1)

          -  Deviate from the following provided range of blood pressure, pulse rate, body
             temperature and standard 12-lead ECG at screening or the hospital admission day (Day
             -1)

          -  Subjects who meet any of the criteria for laboratory tests at screening or the
             hospital admission day (Day -1). Normal ranges of each test specified at the study
             site or the test/assay organization will be used as the normal ranges in this study.

          -  Complication or history of drug allergies

          -  Developed upper gastrointestinal symptoms within 7 days before the hospital admission
             day (Day −1)

          -  Complication or history of hepatic disease

          -  Complication of long QT syndrome, congenital short QT syndrome

          -  A history of gastrointestinal resection

          -  Subjects with a complication or history of endocrine disease

          -  Subjects with a complication or history of malignant tumor

          -  Subjects with a complication or history of lymphatic disease

          -  Applies to any of following concerns of tuberculosis

               -  A history of active tuberculosis

               -  Abnormalities detected on a chest X-ray test (at screening)

               -  Contact with infectious tuberculous patients

          -  Applies to any of following concerns, with regard to infection except for tuberculosis

               -  A complication or history of severe herpes zoster or herpes zoster disseminated

               -  At least twice of relapse of localized herpes zoster

               -  Inpatient hospital care for severe infectious diseases within 90 days before the
                  hospital admission day (Day -1)

               -  Treatment with intravenous antibiotics within 90 days before the hospital
                  admission day (Day -1) (prophylactic antibiotics are not applicable).

               -  Other than above, a subject with a high risk of developing infectious disease
                  (e.g. subjects with urethral catheterisation) in judgment of the investigator or
                  sub-investigator.

          -  Vaccination of live vaccines or live attenuated vaccines within 56 days before the
             hospital admission day (Day -1) (Inactivated vaccines such as influenza vaccine and
             pneumococcal vaccine are not applicable.)

          -  A history of clinically serious allergies

          -  Previously received administration of ASP015K

          -  Excessive alcohol drinking or smoking

        Patients with impaired renal function

          -  Patients who received or are scheduled to receive any new drugs within 14 days before
             the hospital admission day (Day -1)

          -  Patients who receive dialysis, or received renal transplantation

          -  Patients who developed acute changes in renal function and in all laboratory test
             results within 28 days before screening and patients with impaired renal function who
             may need new concomitant therapies during the study period.

          -  Patients with a complication of severe heart disease, NYHA class III or IV cardiac
             failure.

          -  Complication of alimentary disease, cerebrovascular disorder, respiratory disease

          -  Patients with tubular dysfunction, obvious urination impaired

        Subjects with normal renal function

          -  Subjects who received or is scheduled to receive medications (including
             over-the-counter [OTC] drugs) within seven days before the hospital admission day (Day
             -1).

          -  Subjects with a complication or history of heart disease, respiratory disease,
             alimentary disease, renal disease, endocrine disease, urological disease,
             cerebrovascular disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00002</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP015K</keyword>
  <keyword>impaired renal function</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

